Appearance of new CDC-reactive antibodies in patients waiting for kidney transplantation

Eva Marie Pfaff, Inge Derad, Thorsten Feldkamp, Martin Nitschke, Siegfried Görg, Malte Ziemann*

*Corresponding author for this work

Abstract

Background: Patients awaiting kidney transplantation are regularly screened for HLA-antibodies, but there is scarce data about the optimal interval. Methods: Results from Complement-dependent cytotoxicity testing (CDC) for waitlisted patients were reviewed for increases in panel reactive antibodies (PRA) by at least 10%-points. Clinical records were screened for historic immunizing events and possible trigger factors preceding the PRA-increase. Additionally, non-pretransplanted men tested negative for HLA antibodies by solid-phase assays (SPA) out of their first two samples on the waiting list (“non-immunized men”) were evaluated for detection of HLA antibodies by SPA during their further stay on the waiting list. Results: 15,360 samples from 1928 patients tested by CDC were analyzed for changes in PRA. PRA-increases occurred most frequently in patients waitlisted recently for retransplantation (annual incidence 6%). Removal of previous transplants, severe infections and/or reduced immunosuppression triggered 65% of PRA-increases during the first year after waitlisting. Transfusions accounted for 55% of PRA-increases in later years. Leucocyte-reduced red blood cell units not only boosted historic antibodies, but even induced primary immunization. In the second part of the study, 6780 samples tested by SPA from 703 non-immunized men were evaluated for development of HLA-antibodies. Only 9 men (1.3%) turned HLA antibody-positive (annual incidence 0.4%). Conclusion: A uniform screening interval does not fit all: Frequencies should be highest in patients newly waitlisted for re-transplant and lowest in non-immunized men. Transfused patients should be monitored closely for development of HLA-antibodies even if leukoreduced products are used.

Original languageEnglish
Article number101449
JournalTransplant Immunology
Volume69
ISSN0966-3274
DOIs
Publication statusPublished - 12.2021

Funding

This study would have been impossible without all the patients consenting to scientific evaluation of their records. We are also indebted to the patients' nephrologists and thankful for the excellent collaboration.

Fingerprint

Dive into the research topics of 'Appearance of new CDC-reactive antibodies in patients waiting for kidney transplantation'. Together they form a unique fingerprint.

Cite this